Current perspective of neuroprotection and glaucoma
File(s)Current perspective of neuroprotection and glaucoma.pdf (399.7 KB)
Published version
Author(s)
Tian, Kailin
Shibata-Germanos, Shannon
Pahlitzsch, Milena
Cordeiro, M Francesca
Type
Journal Article
Abstract
Glaucoma is the second leading cause of blindness worldwide and is most notably characterized by progressive optic nerve atrophy and advancing loss of retinal ganglion cells (RGCs). The main concomitant factor is the elevated intraocular pressure (IOP). Existing treatments are focused generally on lowering IOP. However, both RGC loss and optic nerve atrophy can independently occur with IOP at normal levels. In recent years, there has been substantial progress in the development of neuroprotective therapies for glaucoma in order to restore vital visual function. The present review intends to offer a brief insight into conventional glaucoma treatments and discuss exciting current developments of mostly preclinical data in novel neuroprotective strategies for glaucoma that include recent advances in noninvasive diagnostics going beyond IOP maintenance for an enhanced global view. Such strategies now target RGC loss and optic nerve damage, opening a critical therapeutic window for preventative monitoring and treatment.
Date Issued
2015-11-11
Date Acceptance
2015-09-26
Citation
CLINICAL OPHTHALMOLOGY, 2015, 9, pp.2109-2118
ISSN
1177-5483
Publisher
DOVE MEDICAL PRESS LTD
Start Page
2109
End Page
2118
Journal / Book Title
CLINICAL OPHTHALMOLOGY
Volume
9
Copyright Statement
© 2015 Tian et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported,
v3.0)
License. The full terms of the License are available at
http://creativecommons.org/licenses/by-nc/3.0
/
. Non-commercial uses of the work are permitted without any further
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on
how to request permission may be found at: http://www.dovepress.com/permissions.php
v3.0)
License. The full terms of the License are available at
http://creativecommons.org/licenses/by-nc/3.0
/
. Non-commercial uses of the work are permitted without any further
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on
how to request permission may be found at: http://www.dovepress.com/permissions.php
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000366380900001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Ophthalmology
glaucoma
retinal ganglion cell
neuroprotection
RETINAL GANGLION-CELLS
OPEN-ANGLE GLAUCOMA
MESENCHYMAL STEM-CELLS
OPTIC-NERVE HEAD
DEATH IN-VIVO
OXIDATIVE STRESS
INTRAOCULAR-PRESSURE
VISUAL-FIELD
VITAMIN-E
NEURODEGENERATIVE DISEASES
Publication Status
Published
Date Publish Online
2015-11-11